Clinical trials: Cancer of Nasopharynx
Nasopharyngeal Carcinoma Patients Treated With Curative Radiotherapy
Massive Nasal Bleeding in Patients With NPC Received Curative RT
To investigate the incidence, predictive markers, and survival impact of massive nasal bleeding in nasopharyngeal carcinoma (NPC) patients who received curative radiotherapy (RT) with/without chemotherapy.
- Trial name
- NCT06348485
- Testing
- Patients without massive nasal bleeding, Patients with massive nasal bleeding
- Where
- Taiwan
- Volunteers
- 1,327 people
- Sponsor
- Taichung Veterans General Hospital
Breast Cancer, Head and Neck Cancer
S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors
RATIONALE: Vandetanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Breast Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT00937417
- Testing
- docetaxel, vandetanib, proteomic profiling
- Sponsor
- SWOG Cancer Research Network
Nasopharyngeal Carcinoma
A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma
The purpose of this research study is to determine how effective and how safe it is to give an Epstein-Barr Virus (EBV) immunotherapy product to participants with nasopharyngeal carcinoma (NPC) associated with EBV that has come…
- Trial name
- NCT00834093
- Testing
- Epstein-Barr Virus Specific Immunotherapy
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Dana-Farber Cancer Institute
Tumor Positron-Emission Tomography
A Head-to-head Comparison of [68Ga]Ga-FAPI and [68Ga]Ga-TATE PET/CT in Patients With Nasopharyngeal Carcinoma: a Single-center, Prospective Study
Both fibroblast activation protein (FAP)-targeted imaging and somatostatin receptors (SSTR)-targeted imaging were the promising imaging modalities for the diagnosis of primary and metastatic nasopharyngeal carcinoma (NPC).
- Trial name
- NCT05990998
- Testing
- 68Ga-DOTATATE and 68Ga-FAPI
- Where
- China
- Volunteers
- 38 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Nasopharyngeal Carcinoma (NPC)
Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma.
This study plans to enroll patients with histologically or cytologically confirmed locally recurrent nasopharyngeal carcinoma. After signing informed consent, eligible subjects will receive three cycles of standard-dose becotatug…
- Trial name
- NCT07781358
- Testing
- Becotatug Vedotin, PD-1 / PD-L1 monoclonal antibody
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Hongmeng Yu
Lung Metastatic Nasopharyngeal Carcinoma
A Real-world Study of the Efficacy and Safety of PD-1 Inhibitors Combined With Chemoradiotherapy in Lung Metastatic Nasopharyngeal Carcinoma
This study is a retrospective real-world study. In this study, we plan to collect the clinical data of lung metastatic nasopharyngeal carcinoma patients who received PD-1 inhibitors and chemotherapy combined with or without…
- Trial name
- NCT07062484
- Testing
- Control: gemcitabine, cisplatin, tirelizumab, Experimental: gemcitabine, cisplatin, tirelizumab and radiotherapy
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Recurrent Nasopharyngeal Carcinoma
MK-2206 in Recurrent Nasopharyngeal Carcinoma
To evaluate the activity and safety of MK-2206 in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC)
- Trial name
- MC1079 (NCT01370070)
- Testing
- MK-2206
- Where
- Hong Kong
- Volunteers
- 12 people
- Sponsor
- Chinese University of Hong Kong
Nasopharyngeal Carcinoma, Toripalimab
Concurrent Chemoradiotherapy With Toripalimab for Local-regional Recurrent Nasopharyngeal Carcinoma: a Prospective, Single-arm, Phase II Trial
This is a prospective, single-arm, phase II trial to study the efficacy of PD-1 antibody Toripalimab combined with concurrent cisplatin chemoradiotherapy in treating patients with locoregionally recurrent nasopharyngeal carcinoma.
- Conditions
- Nasopharyngeal Carcinoma, Toripalimab, Recurrent Nasopharyngeal Squamous Cell Carcinoma
- Trial name
- NCT04992988
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Cancer Hospital of Guangxi Medical University
Nasopharyngeal Carcinoma
The Role of Concurrent Chemotherapy for Lower Risk Locally Advanced Nasopharyngeal Carcinoma(NPC) in the Era of IMRT
The purpose of this study is to verify that simultaneous integrated boost IMRT (SIB-IMRT) alone is non-inferior to SIB-IMRT combined with concurrent chemotherapy for low-risk locally advanced nasopharyngeal carcinoma.
- Trial name
- NCT01817023
- Testing
- SIB-IMRT, Cisplatin
- Where
- 6 sites in China
- Volunteers
- 590 people
- Sponsor
- Chinese Academy of Medical Sciences
Nasopharyngeal Carcinoma
Retrospective Study About Nasopharyngeal Carcinoma at C. S. Parc Tauli
Retrospective study of patients diagnosed with a nasopharyngeal carcinoma included in our data base care between June 1990 and September 2013.
- Trial name
- NCT02199132
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Corporacion Parc Tauli
Cancer
Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00904514
- Testing
- gene expression analysis, microarray analysis, mutation analysis
- Volunteers
- 241 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Nasopharyngeal Carcinoma
Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
- Trial name
- NCT03025958
- Testing
- Nimotuzumab, Radiation
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Neoplasms, Carcinoma
Docetaxel in Combination With Cisplatin-5-fluorouracil for the Induction Treatment of Nasopharyngeal Carcinoma in Children and Adolescents
The primary objective is to estimate the Complete Response rate of docetaxel to the combination of cisplatin-5-fluorouracil (TCF) compared to cisplatin-5-fluorouracil (CF) in the Induction treatment of Nasopharyngeal Carcinoma…
- Trial name
- NCT00565448
- Testing
- docetaxel, cisplatin, 5-fluorouracil
- Where
- 26 sites in Algeria, Brazil and 12 more
- Volunteers
- 75 people
- Sponsor
- Sanofi
Dysphagia
Multifunctional Nutrition Tube in Dysphagia for Nasopharyngeal Carcinoma
Baseline information (demographics, medical history, etc.), nutritional status at admission and after treatment, depression, dysphagia, and quality of life (QOL) after treatment as well as adverse events are compared.
- Trial name
- NCT06328868
- Testing
- Intermittent Oral-esophageal Tube Feeding, Nasogastric Tube Feeding, comprehensive rehabilitation therapy
- Volunteers
- 80 people
- Sponsor
- Copka Sonpashan
Nasopharyngeal Cancer, Neoplasm Metastasis
Oligo-metastases NPC Patients Received Radiation for Primary Tumors and Treatments for Metastatic Lesions
Oligo-metastases NPC patients received radiation for primary tumors and treatments for metastatic lesions.
- Trial name
- NCT03129412
- Testing
- radical radiotherapy
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma
To Study the Feasibility and Quality of Life of Medial Group Retropharyngeal Node Sparing in Nasopharyngeal Carcinoma
This is an randomized, controlled, phase 3 clinical trial. The purpose of this study is to evaluate whether medial group retropharyngeal node （MRLN） sparing could reduce the incidence of radiation-caused dysphagia and improve…
- Trial name
- NCT03346109
- Testing
- medial group retropharyngeal node（MRLN） sparing
- Where
- China
- Volunteers
- 568 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma
The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC
The purpose of this study is to preliminarily evaluate anti-tumor activity of a Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Infusion (JS001) in treating advanced gastric adenocarcinoma, esophageal squamous cell…
- Conditions
- Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Nasopharyngeal Carcinoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT02915432
- Testing
- 3 mg/kg anti-PD-1 mAb JS001 Q2W, 360 mg anti-PD-1 mAb JS001 Q3W, 240mg anti-PD-1 mAb JS001 Q3W
- Where
- 23 sites in China
- Volunteers
- 401 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Advanced Nasopharyngeal Carcinoma
SBRT Combined With Chemotherapy and Tislelizumab in Metastatic NPC
Radiotherapy and immunotherapy have achieved good survival benefit in advanced nasopharyngeal carcinoma. A number of clinical studies of immunotherapy combined with radiotherapy for nasopharyngeal carcinoma are also ongoing.
- Trial name
- NCT05652192
- Testing
- SBRT
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Zhejiang Cancer Hospital
Nasopharyngeal Carcinoma
Fosaprepitant for the Prevention of Nausea and Emesis During Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma
This is an opene-label, single center, randomized prospective pilot study to compare the efficacy of weekly versus triweekly fosaprepitant regimens for the prevention of nausea and emesis during concurrent chemoradiotherapy for…
- Trial name
- NCT04636632
- Testing
- fosaprepitant
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Head and Neck Cancer
Pilot Study of Pulmozyme (rhDNase) in Patients With Head and Neck Cancers Treated With Radiation Therapy + Chemotherapy
RATIONALE: Nebulized dornase alfa inhalation solution may decrease the thickness of saliva in the mouth and improve quality of life in patients undergoing radiation therapy and chemotherapy for head and neck cancer.
- Trial name
- NCT00536952
- Testing
- Pulmozyme, Radiation Therapy
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Northwestern University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.